Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...
December 2021 Top Biopharma Deal: Foghorn – Loxo using Gene Traffic Control for New Oncology Treatments
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- Loxo (Eli Lilly) will use Foghorn’s proprietary Gene Traffic Control platform to discover and develop therapeutic molecules directed to a BRM target and an additional undisclosed oncology target, plus three additional discovery programs.
- Foghorn will receive $300M up front, $80M in an upfront equity investment (4,000,000 shares of common at $20.00 per share), and is eligible to receive up to $1.3B in development, regulatory, and sales milestones based on Foghorn’s option to participate in the U.S. costs/profits.
- 50/50 U.S. cost/profit share for the BRM-selective program and one other undisclosed target. For the three discovery programs, Foghorn has an option to split U.S. costs/profits following the successful completion of dose-finding toxicity studies.
- Ex-U.S. BRM-selective program and one other undisclosed target: Tiered low-double digit to the twenties royalties. Ex-U.S. other undisclosed target: Tiered mid-single digit to low-double digit royalties subject to royalty step-down provisions.
Congrats to Foghorn and Loxo for landing DealForma’s December 2021 Top Biopharma Deal. Last month’s Deal of the Month was Owkin and Sanofi’s partnership for Owkin’s AI and federated learning platform to advance Sanofi’s oncology pipeline. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...
Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...